Par Pharma in deal with AstraZeneca for generic Accolate; J&J unit sues Mylan and Lupin over Prezista

24 November 2010

US generic drugmaker Par Pharmaceutical (NYSE: PRX) has entered into an exclusive supply and distribution agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN) in the USA to distribute the authorized generic version of the latter’s asthma drug Accolate (zafirlukast).

Par said it began shipping 10mg and 20mg strengths of zafirlukast tablets on Friday, November 19. Financial details of the deal between the two companies were not disclosed. According to IMS Health data, annual sales in the USA for Accolate are approximately $50 million.

Zafirlukast tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK